Targeting PI3 kinase in cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The phosphoinositide 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway is a key signaling cascade frequently dysregulated in human cancers.
• Aberrant activation of this pathway can occur through various genetic alterations and contributes to oncogenesis and therapeutic resistance.
• mTOR inhibitors represent the first-generation targeted therapies, with several already approved for clinical use.

Purpose of the Study:

• To review the clinical development of PI3K inhibitors targeting the PI3K/Akt/mTOR pathway.
• To discuss different classes of PI3K inhibitors, including dual PI3K/mTOR, pan-PI3K, and isoform-selective agents.
• To analyze the challenges and future directions for PI3K/Akt/mTOR pathway inhibitors in cancer therapy.

Main Methods:

• Literature review of clinical trials and preclinical studies on PI3K inhibitors.
• Analysis of data regarding the efficacy, safety, and mechanisms of action of various PI3K inhibitors.
• Discussion of current challenges, including adverse events and therapeutic resistance.

Main Results:

• Multiple PI3K inhibitors are in clinical development, targeting different aspects of the PI3K/Akt/mTOR pathway.
• Common toxicities such as hyperglycemia and gastrointestinal issues limit the therapeutic window for most PI3K inhibitors.
• Single-agent activity is generally limited, except for isoform-selective PI3Kδ and PI3Kγ inhibitors in hematologic malignancies.

Conclusions:

• The clinical utility of PI3K inhibitors is constrained by their toxicity profile and modest single-agent efficacy.
• Future success hinges on identifying predictive biomarkers for patient selection and exploring rational combination therapies.
• Targeting the PI3K/Akt/mTOR pathway remains a promising strategy, but requires further refinement for optimal clinical application.